Constantine J Karvellas1, Holly Tillman2, Alexander A Leung3, William M Lee4, Michael L Schilsky5, Bilal Hameed6, R Todd Stravitz7, Brendan M McGuire8, Oren K Fix9. 1. Divisions of Hepatology and Critical Care Medicine, University of Alberta, Edmonton, AB, Canada. 2. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA. 3. Division of Endocrinology and Metabolism, University of Calgary, Calgary, AB, Canada. 4. Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 5. Division of Digestive Diseases and Transplant and Immunology, Yale University School of Medicine, New Haven, CT, USA. 6. Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, CA, USA. 7. Division of Gastroenterology and Hepatology, Virginia Commonwealth University, Richmond, VA, USA. 8. Division of Gastroenterology and Hepatology, University of Alabama, Birmingham, AL, USA. 9. Organ Transplant Program, Swedish Medical Center, Seattle, WA, USA.
Abstract
BACKGROUND & AIMS: Published estimates of survival associated with mushroom (amatoxin)-induced acute liver failure (ALF) and injury (ALI) with and without liver transplant (LT) are highly variable. We aimed to determine the 21-day survival associated with amatoxin-induced ALI (A-ALI) and ALF (A-ALF) and review use of targeted therapies. METHODS: Cohort study of all A-ALI/A-ALF patients enrolled in the US ALFSG registry between 01/1998 and 12/2014. RESULTS: Of the 2224 subjects in the registry, 18 (0.8%) had A-ALF (n = 13) or A-ALI (n = 5). At admission, ALF patients had higher lactate levels (5.2 vs. 2.2 mm, P = 0.06) compared to ALI patients, but INR (2.8 vs. 2.2), bilirubin (87 vs. 26 μm) and MELD scores (28 vs. 24) were similar (P > 0.2 for all). Of the 13 patients with ALF, six survived without LT (46%), five survived with LT (39%) and two died without LT (15%). Of the five patients with ALI, four (80%) recovered and one (20%) survived post-LT. Comparing those who died/received LT (non-spontaneous survivors [NSS]) with spontaneous survivors (SS), N-acetylcysteine was used in nearly all patients (NSS 88% vs. SS 80%); whereas, silibinin (25% vs. 50%), penicillin (50% vs. 25%) and nasobiliary drainage (0 vs. 10%) were used less frequently (P > 0.15 for all therapies). CONCLUSION: Patients with mushroom poisoning with ALI have favourable survival, while around half of those presenting with ALF may eventually require LT. Further study is needed to define optimal management (including the use of targeted therapies) to improve survival, particularly in the absence of LT.
BACKGROUND & AIMS: Published estimates of survival associated with mushroom (amatoxin)-induced acute liver failure (ALF) and injury (ALI) with and without liver transplant (LT) are highly variable. We aimed to determine the 21-day survival associated with amatoxin-induced ALI (A-ALI) and ALF (A-ALF) and review use of targeted therapies. METHODS: Cohort study of all A-ALI/A-ALFpatients enrolled in the US ALFSG registry between 01/1998 and 12/2014. RESULTS: Of the 2224 subjects in the registry, 18 (0.8%) had A-ALF (n = 13) or A-ALI (n = 5). At admission, ALFpatients had higher lactate levels (5.2 vs. 2.2 mm, P = 0.06) compared to ALI patients, but INR (2.8 vs. 2.2), bilirubin (87 vs. 26 μm) and MELD scores (28 vs. 24) were similar (P > 0.2 for all). Of the 13 patients with ALF, six survived without LT (46%), five survived with LT (39%) and two died without LT (15%). Of the five patients with ALI, four (80%) recovered and one (20%) survived post-LT. Comparing those who died/received LT (non-spontaneous survivors [NSS]) with spontaneous survivors (SS), N-acetylcysteine was used in nearly all patients (NSS 88% vs. SS 80%); whereas, silibinin (25% vs. 50%), penicillin (50% vs. 25%) and nasobiliary drainage (0 vs. 10%) were used less frequently (P > 0.15 for all therapies). CONCLUSION:Patients with mushroom poisoning with ALI have favourable survival, while around half of those presenting with ALF may eventually require LT. Further study is needed to define optimal management (including the use of targeted therapies) to improve survival, particularly in the absence of LT.
Authors: Ferit Çelik; Nalan Gülşen Ünal; Ali Şenkaya; Seymur Aslanov; Abdullah Murat Buyruk; İlker Turan; Fulya Günşar; Ahmet Ömer Özütemiz; Abdullah Zeki Karasu Journal: Turk J Gastroenterol Date: 2021-08 Impact factor: 1.852
Authors: Fethi Gül; İsmet Sayan; Hüseyin Arıkan; Sinan Karacabey; Mustafa Kemal Arslantaş; İsmail Cinel Journal: Turk J Anaesthesiol Reanim Date: 2019-10-08
Authors: Joshua Hefler; Braulio A Marfil-Garza; Rena L Pawlick; Darren H Freed; Constantine J Karvellas; David L Bigam; A M James Shapiro Journal: PeerJ Date: 2021-12-09 Impact factor: 2.984
Authors: Iadarilang Tiewsoh; Prasanta K Bhattacharya; Bhupen Barman; Himesh Barman; Kamwamangika Rapthap; Lima Sangla; Kyrshanlang G Lynrah Journal: J Family Med Prim Care Date: 2022-05-14
Authors: Ganesh Raghu; Michael Berk; Peter A Campochiaro; Hartmut Jaeschke; Giancarlo Marenzi; Luca Richeldi; Fu-Qiang Wen; Ferdinando Nicoletti; Peter M A Calverley Journal: Curr Neuropharmacol Date: 2021 Impact factor: 7.363